OCUPHARM DIAGNOSTICS SL

Their core work

OcuPharm Diagnostics is a Madrid-based SME specializing in ocular diagnostics and therapeutics, with a focus on developing diagnostic biomarkers and drug delivery solutions for eye diseases. They began by validating a novel diagnostic biomarker for Dry Eye Syndrome and have since expanded into ocular drug delivery, formulation science, and posterior segment disease research. Their repeated involvement in Marie Skłodowska-Curie training networks (MSCA-RISE and MSCA-ITN) shows they actively bridge industry and academia, hosting researchers and contributing industry-grade ocular models and testing capabilities.

What they specialise in

How they've shifted over time

OcuPharm started in 2015 with a narrow, product-oriented focus: validating a specific diagnostic biomarker for Dry Eye Syndrome through the SME Instrument. From 2017 onward, they shifted toward broader ocular drug delivery and therapeutic research, embedding themselves in large MSCA training networks that span oncology, eye therapeutics, and eventually CNS dysfunction. The trajectory shows a company moving from diagnostics toward a wider therapeutic platform, now covering drug formulations, medical devices, and disease modelling across both eye and brain applications.

OcuPharm is expanding from pure ocular diagnostics toward a broader therapeutic scope including CNS dysfunction, suggesting future interest in neuro-ophthalmology and cross-organ drug delivery partnerships.

How they like to work

OcuPharm primarily joins consortia as a participant (3 of 4 projects), contributing industry expertise to academic-led training networks. Their single coordination was an SME Instrument project — a solo venture typical of early-stage product validation. With 43 unique partners across 13 countries, they have built a remarkably wide network for a small company, indicating they are well-connected and comfortable operating in large, international consortia.

OcuPharm has collaborated with 43 unique partners across 13 countries, a substantial network built primarily through large MSCA training consortia. Their partnerships span academic institutions and industry players across Europe, with strong ties to the ocular and pharmaceutical research community.

What sets them apart

OcuPharm occupies a rare niche as a diagnostic-and-therapeutic SME focused specifically on eye diseases, combining industry-grade testing capabilities with deep academic network ties. Their triple involvement in MSCA networks means they have trained and hosted researchers from across Europe, giving them an unusually rich talent pipeline and collaborative reputation for their size. For consortium builders, they offer the combination of a commercial SME perspective with hands-on expertise in ocular models and formulations — a profile that is hard to find outside large pharma.

Highlights from their portfolio

• DryEye
  Their only coordinated project and an SME Instrument Phase 1 — indicates they had a specific product (diagnostic biomarker for Dry Eye Syndrome) ready for market validation.
• ORBITAL
  Most keyword-rich project covering drug delivery, ocular modeling, formulations, medical devices, and multiple model types — represents the fullest expression of their capabilities.
• CRYSTAL3
  Their most recent and strategically significant project, extending their ocular expertise into CNS dysfunction and signalling a potential new direction for the company.